Book a Meeting

Anti-CD3 Recombinant Immunotoxin (DT389-UCHT1(sFv)) (CAT#: BioBet-IT038Z) Datasheet

Target
CD3
IT Type
Antibody-based IT
Description
An immunotoxin, comprising a mutant diphtheria toxin moiety linked to a targeting moiety- a antibody fragment specific for a cell surface antigen CD3.
Indication
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
Classification
Immuntoxin; biobetter
Construction
DT389-UCHT1(sFv)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD3
Full Name
cluster of differentiation 3
Background
CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells).
Alternative Names
CD3
Antibody Clone
UCHT1
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Type
scFv
Host
Mouse
Species Reactivity
Human
Antibody Indication
Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma
Toxic Moiety
DT390
Organism
Corynebacterium
Family
Diphtheria toxin
Molecular Mass
35.64 kD
Toxic MOA
Diphtheria toxin (DT) is one of the most extensively studied bacterial toxins with intracellular action. The first 390 amino acid residues of DT (DT390) contain the catalytic domain or A chain of DT that inhibits protein synthesis by ADP ribosylation of elongation factor 2 (EF-2) and the translocation domain that translocates the catalytic domain to the cytosol by interaction with cytosolic Hsp90 and thioredoxin reductase.

The antibody portion mediated selective binding to target cells, while the toxin portion mediated translocation into the cytosol and subsequent cell killing.

Head and neck cancer, melanoma, and renal cell, ovarian, and colorectal carcinoma

Related Products

Anti-CD3 Recombinant Immunotoxin (DT390scfbDb(UCHT1)) (CAT#: BioBet-IT033Z)
Anti-CD3 Recombinant Immunotoxin (FN18-CRM9) (CAT#: BioBet-IT034Z)
Anti-CD3 Recombinant Immunotoxin (UCHT1-CRM9) (CAT#: BioBet-IT037Z)
Anti-CD3 Recombinant Immunotoxin (scFv (UCHT-1) -PE38) (CAT#: BioBet-IT039Z)
Anti-CD3 Recombinant Immunotoxin (CD3-CRM9) (CAT#: BioBet-IT040Z)
Anti-CD3 Recombinant Immunotoxin (sFvDT390) (CAT#: BioBet-IT035Z)
Anti-CD3 Recombinant Immunotoxin (DT390scfbDb(C207)) (CAT#: BioBet-IT032Z)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.